Oncolytic Virotherapy and its Current Progress

References

1. Andtbacka, R.H. et al. (2015). Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J. Clin. Oncol. 33, 2780-2788. (DOI:10.1200/JCO.2014.58.3377)
2. Cheema, T.A. et al. (2013). Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl. Acad. Sci. USA. 110, 12006-12011. (DOI:10.1073/pnas.1307935110)
3. Chiocca, E.A. and Rabkin, S.D. (2014). Oncolytic Viruses and Their Application to Cancer Immunotherapy. Can. Immunol. Res. 2, 295-300. (DOI:10.1158/2326-6066.CIR-14-0015)
4. Cunningham, A.L., Donaghy, H., Harman, A.N. and Kim, M. (2010). Manipulation of dendritic cell function by viruses. Curr. Opin. Microbiol. 13, 524-529. (DOI:10.1016/j.mib.2010.06.002)
5. Yoo, S.Y. et al. (2017). Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators of Inflamm. 2017, 6. https://doi.org/10.1155/2017/5198798
6. Diaz, R.M. et al. (2007). Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus. Cancer Research. 2007, 67, 2840-2848. (DOI:10.1158/0008-5472.CAN-06-3974)
7. Fukuhara, H., Ino, Y. and Todo, T. (2016). Oncolytic Virus Therapy: A new era of cancer treatment at dawn. Cancer Science. 107, 1373–1379. (DOI:10.1111/cas.13027)
8. Genelux, (2017). What Is Oncolytic Virotherapy. n.d. Web. 23 July 2017. http://www.genelux.com/leadership-in-oncolytic-virotherapy/oncolytic-virotherapy/
9. Helwick, C. (2016). Combination Strategies Harness the Power of the Oncolytic Virus Talimogene Laherparepvec. The Asco Post. 10 Nov. 2016. http://www.ascopost.com/issues/november-10-2016/combination-strategies-harness-the-power-of-the-oncolytic-virus-talimogene-laherparepvec/
10. Heo, J. et al. (2011). Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170–1179. (DOI:10.1038/mt.2011.39)
11. Heo, J. et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336. (DOI:10.1038/nm.3089)
12. Ino, Y. and Todo, T. (2010). Clinical development of a third-generation oncolytic HSV-1 (G47Δ) for malignant glioma. Ther. Regul. 5, 10-11. (DOI:10.1142/S1568558610000185)
13. Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Dis. 14, 642-662. (DOI:10.1038/nrd4663)
14. Nakashima, H., Kaur, B. and Chiocca, E.A. (2010). Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev. 21, 119–126. (DOI:10.1016/j.cytogfr.2010.02.004)
15. Park, B.H. et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533–542. (DOI:10.1016/S1470-2045(08)70107-4)
16. Potts, K.G. et al. (2017). Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Mole. Med. 9, 638-654. (DOI:10.15252/emmm.201607296)
17. Puzanov, I. et al. (2016). Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-Vec) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J. Clin. Oncol. 34, 2619-2626. (DOI:10.1200/JCO.2016.67.1529)
18. Sanchez-Carbayo, M. et al. (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778–789. (DOI:10.1200/JCO.2005.03.2375)
19. Varghese, S. et al. (2006). Enhanced therapeutic efficacy of a cytokine expressing oncolytic herpes simplex virus against prostate cancer. Can. Gene Ther. 13, 253-265. (DOI:10.1038/sj.cgt.7700900)